A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk

Age of Diagnosis of Breast Cancer in China: Almost 10 Years Earlier than in the United States and the European Union

(2015) Qing-Kun Song et al.   Asian Pacific Journal of Cancer Prevention

Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin

(2014) Abdul Hameed Baloch et al.   MOLECULAR BIOLOGY REPORTS

About 1% of the breast and ovarian Spanish families testing negative forBRCA1andBRCA2are carriers ofRAD51Dpathogenic variants

(2013) Sara Gutiérrez-Enríquez et al.   INTERNATIONAL JOURNAL OF CANCER

DNA repair genes are selectively mutated in diffuse large B cell lymphomas

(2013) Noel FCC de Miranda et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hereditary Breast Cancer: The Era of New Susceptibility Genes

(2013) Paraskevi Apostolou et al.   Biomed Research International

The CHEK2 I157T Variant and Breast Cancer Susceptibility: A Systematic Review and Meta-analysis

(2012) Chuan Liu et al.   Asian Pacific Journal of Cancer Prevention

DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL-Induced Leukemogenesis In Vivo

(2012) Sylvia Takacova et al.   CANCER CELL

Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families

(2012) Ana Osorio et al.   HUMAN MOLECULAR GENETICS

Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer

(2011) Cezary Cybulski et al.   JOURNAL OF CLINICAL ONCOLOGY

A mammalian functional-genetic approach to characterizing cancer therapeutics

(2010) Hai Jiang et al.   Nature Chemical Biology

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

(2010) Alfons Meindl et al.   NATURE GENETICS

Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China

(2009) A-Yong Cao et al.   BREAST CANCER RESEARCH AND TREATMENT

Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response

(2009) Travis H. Stracker et al.   DNA REPAIR

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase

(2009) Zhenjian Cai et al.   MOLECULAR CELL

Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: Not present in the Chinese familial breast cancer population

(2008) Wang Chen et al.   ADVANCES IN THERAPY

Identification of a novel CHEK2variant and assessment of its contribution to the risk of breast cancer in French Canadian women

(2008) David J Novak et al.   BMC CANCER

CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls

(2008) Maren Weischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer in Chinese Women Younger than Age 40: Are They Different from Their Older Counterparts?

(2008) Ava Kwong et al.   WORLD JOURNAL OF SURGERY